About Venn TherapeuticsAt Venn Therapeutics, we are focused on developing novel, first-in-class drugs that polarize tumor-resident innate immune cells to an anti-tumor phenotype and reverse the immunosuppressive microenvironment found within tumors. Powering the immune system is our focus and we welcome the opportunity to work with other companies to advance innovative cancer therapies from research labs to patient bedside. Our approach has been to form collaborations with academic researchers in order to fund the development and clinical validation of novel immunotherapies.
CEO: Sam Shrivastava
Please click here for ImmunoMet Therapeutics' pipeline.
2 articles with Venn Therapeutics
What if you could more precisely control CAR-T cells using FDA-approved small molecules to enhance their activity against solid tumors? That’s exactly what Obsidian Therapeutics is aiming to do.
Promising New Cancer Therapy Developed Via Michigan State University And Venn Therapeutics Partnership